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ABSTRACT 
Background: Telomeres are known to provide genomic stability and telomere length 
has been associated with cardiovascular diseases. Moreover, a higher telomerase 
activity has been shown to be associated with ventricular arrhythmias (VA) in 
ischaemic cardiomyopathy. Increasing evidence suggests that genetic variation in 
key telomere genes has an impact on telomerase activity. Each copy of the minor 
allele of SNP rs12696304, at a locus including TERC (telomerase) has been 
associated with ~ 75 bp reduction in mean telomere length likely mediated by an 
effect on TERC expression. We investigated the impact of genetic variation of this 
SNP on telomerase and its association with VA in ischaemic cardiomyopathy 
patients. 
Methods and Results: 90 ischaemic cardiomyopathy patients with primary 
prevention ICDs were recruited. 35 received appropriate ICD therapy for potentially-
fatal VA (cases) while the remaining 55 patients did not (controls). No significant 
differences in baseline demographics were seen between the groups. TS was 
measured by qPCR, telomerase activity by TRAP assay and SNP genotyping with 
Taqman probes. Telomerase was highest in C homozygous allele and had a 
significant association with VA in this group only (C/C,C/G,G/G; p-value 0.04, 0.33, 
0.43). 
Conclusion: The present study is the first to examine the association between 
telomerase, a SNP at a locus including TERC and VA in ischaemic cardiomyopathy 
patients. Homozygosity for C-allele significantly effects telomerase expression and its 
association with VA in this cohort. Large-scale prospective studies are required to 
determine if this genetic variation predisposes patients to greater arrhythmic 
tendency post MI. 
 
Keywords: Telomerase, TERC, SNP genotyping, Ventricular arrhythmia  
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INTRODUCTION 
Telomeres are terminal sequences (TTAGGG) of linear eukaryotic chromosomes 
that are involved in maintaining genomic stability and regulating cellular proliferation.1 
Telomeres shorten with every cell division, as DNA polymerase is not able to fully 
replicate the 3’ end of the DNA strand. Progressive telomere shortening in somatic 
cells is a potential mechanism for a biological clock that determines cellular 
behaviour and is thought to trigger cell senescence and premature biological ageing.2 
In addition to this replicative senescence, telomeres can undergo more stochastic 
shortening secondary to external stimuli including oxidative stress.3 Maintenance of 
telomere length is regulated by telomerase, a ribonucleoprotein enzyme consisting of 
a reverse transcriptase (TERT) and a RNA template (TERC) that facilitates addition 
of the telomere repeat sequence.4 
 Evidence suggests that some types of cardiac diseases represent a 
disease of premature biological ageing. Telomere length, independent of 
chronological age, has shown to be associated with coronary artery disease,5 
premature myocardial infarction,6 poor renal function in heart failure,7 poor left 
ventricular ejection fraction8 and cardiovascular risk factors.9 More recently, our 
group has demonstrated that leukocyte telomere biology (critically short telomeres 
and telomerase activity) has a significant association with incidence of potentially-
fatal ventricular arrhythmia (VA) in patients with ischaemic cardiomyopathy.10 
Moreover, there was no significant association between age, sex and WCC adjusted 
mean telomere length and ICD therapy for potentially-fatal VA (p-value 0.88).10 
Telomere length has a strong genetic determination, with heritability 
estimates ranging from 44% to 80%.11, 12 The telomere hypothesis postulates that 
shorter inherited telomeres could represent a primary abnormality predisposing to an 
increased risk of cardiovascular ageing. Since a substantial proportion of the marked 
inter-individual variation in telomere length is genetically determined,11,13,14 this 
should be taken into consideration when analysing inter-individual variability. The 
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concept of genetics and heredity of telomere biology has emerged given the high 
inter-individual variation in telomere length across newborns 15-18 and in individuals of 
the same age group, telomere length in poorly proliferating cells reflecting the 
telomere length found during early development, telomere length comparisons across 
monozygotic and dizygotic twins and the association of paternal age at conception 
and telomere length heritability.19 The vast majority of gene loci that have been 
associated with telomere length encode the TERT and TERC components of the 
enzyme telomerase.13,20 Increasing evidence suggests that genetic variation in key 
genes has an impact on telomerase activity. A genome wide association analysis of 
mean telomere length (in 2917 individuals with follow-up replication in 9492 
individuals), identified an association between telomere length on 3q26 (rs 
12696304, combined p = 3.72 x 10-14) at a locus that includes TERC, which encodes 
the telomerase RNA component. Each copy of the minor allele of rs12696304 was 
associated with a ~ 75 bp reduction in mean telomere length, equivalent to ~ 3.6 
years of age related telomere length attrition. This association was thought to be 
mediated by an effect on TERC expression although telomerase activity was not 
measured.20 
Thus genetically determined telomerase expression influences telomere 
length but its functional impact on somatic cells (where telomerase is largely 
suppressed) is unknown. Following on from our previous study demonstrating a 
significant association between telomere biology and VA10 and recent evidence 
suggesting genetic determination of telomere biology, it was hypothesised:  
(a) Telomerase activity will be different across different genotypes of the SNP 
12696304 on chromosome 3q26 and  
(b) Differential telomerase activity across genotypes would have an impact on 
cardiovascular ageing and hence the incidence of VA in this cohort.  
To test this hypothesis, the current case-control study was designed 
examining the association between genetic variation in SNP 12696304 and leukocyte 
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telomere biology (telomerase activity and mean telomere length) with incidence of 
cardiac arrhythmia (VA) in ischaemic cardiomyopathy patients.   
 
METHODS 
Study Design: 
Retrospective, cross sectional, case-control study. This study was approved by the 
local research ethics committee. All patients gave written informed consent. The 
study protocol conforms to the ethical guidelines of the 1975 Declaration of Helsinki 
as reflected in a priori approval by the institution’s human research committee. 
Patients were recruited at St Bartholomew’s Hospital over one year. All laboratory 
telomere analysis and genotyping was carried out blinded to clinical data at William 
Harvey Research Institute. 
Subjects: 
Patients were included if they met the following criteria: (1) caucasian ethnicity, (2) 
previous MI with coronary artery disease demonstrated on angiography, (3) LVEF≤ 
35% and (4) ICD implanted for primary prevention (risk of SCD due to ischaemic 
cardiomyopathy). These criteria were used to improve uniformity across the patient 
group and to limit the effects of other causes of telomere length variation thereby 
representing the majority of the recruiting centre’s patient population.21 
 Patients were excluded if they met any of the following criteria: (1) age 
<18 yrs, (2) chronic inflammatory disorders judged by patients’ medical history, white 
cell count and serum CRP level, (3) carcinoma, (4) life expectancy less than 6 
months as a result of non-cardiac disease and (5) inability to sign the consent form.  
Patient assessment and investigations: 
Clinical 
A standard questionnaire was filled in for all enrolled patients. Clinical details were 
obtained at recruitment by interviewing the patient and by examining their hospital 
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records. The questionnaire recorded their medical history (to identify hypertension, 
diabetes, chronic renal failure, hypercholesterolemia, smoking status, family history 
of ischaemic heart disease and any other significant medical conditions), drug 
history, NYHA class, details of ICD implant, programming and previous arrhythmia 
history.  
 At recruitment, the patients also underwent a trans-thoracic echocardiogram 
to assess left ventricular function (LVEF measured by modified simpsons method), 
peripheral venous blood sample for general labs (including renal function, 
inflammatory markers - WCC and CRP, lipid profile), brain natriuretic peptide (BNP) 
and telomere genotyping. 
 Potentially-fatal VA was defined as sustained ventricular tachycardia > 170 
bpm or ventricular fibrillation, requiring device therapy. 
Telomere analysis 
Telomere length and Telomerase activity 
Whole blood was drawn into EDTA vacutainers and aliquots separated by density 
gradient centrifugation to yield concentrated leukocyte fraction (Buffy coat), which 
was used to isolate genomic DNA using QIAgen DNeasy Blood and Tissue Kits.  
Using the isolated DNA, mean telomere length was measured by a modified 
version of the quantitative polymerase chain reaction (PCR) based technique that 
compares telomere repeat sequence copy number to single copy gene (36b4) copy 
number in a given sample.22-24 Samples were run in duplicate and a calibrator k562 
run in all PCR reactions to allow comparison across runs.  
 Telomerase activity was assessed in whole leucocyte extracts obtained from 
thawed buffy coats using a commercially available standard PCR – ELISA kit 
(Roche).25 Each assay included telomerase positive control samples (included in the 
kit) and negative controls (heat inactivated samples). All samples were run in 
duplicate.      
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SNP Genotyping  
Taqman SNP genotyping and allelic discrimination were used to genotype patients to 
assess the association of genetic variation in telomere related SNP and ventricular 
arrhythmias.  
All laboratory analyses were performed blinded to clinical data. 
 
Statistical Analyses: 
Statistical analyses were carried out using SAS VERSION 9.3 software. Continuous 
variables are reported as mean ± standard deviation, or median (range) if not 
normally distributed. Characteristics of cases and controls were compared using chi-
squared test for categorical variables and unpaired t-test for continuous variables if 
normally distributed or Mann-Whitney U test if not normally distributed. The effect of 
age, gender, WCC, genotype and other individual cardiovascular risk factors on 
telomere biology in individual genotypes was assessed using a logistic regression 
model. The individual genotype (telomere SNP rs 12636904), as a risk factor for 
appropriate ICD therapy for potential fatal VA (surrogate for SCD), alone and in 
combination with telomere biology (mean telomere length and every 1 unit increase 
in telomerase activity) was assessed using logistic regression. 
 
RESULTS 
Study Patients: 
90 patients were enrolled in this study. Of these 35 were in the case arm 
(potentially-fatal VA) and 55 in the control arm (no potentially-fatal VA). There was no 
significant difference in the two groups in baseline demographics as shown in Table 
1. 
In the case arm, the vast majority of patients (93%) had appropriate therapies 
for ventricular tachycardia. Only 2 out of the 35 cases had ventricular fibrillation that 
required ICD therapy. Both of these patients received therapy for ventricular 
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tachycardia as well during the study follow-up period. The number of therapies for VA 
ranged from 1 to 12 (mean ± SD, 3.82 ± 3.50). Inappropriate therapy for rapidly 
conducted atrial fibrillation was seen in six patients. However, these patients also 
received ICD therapy for VAs and hence were included in the case arm of the study. 
 
Potentially-fatal VA and Genotype: 
There were 20 cases and 24 controls in the C/C genotype, 10 cases and 22 controls 
in C/G genotype and 5 cases and 9 controls in the GG genotype. A univariate 
analysis examining the association of potentially-fatal VA and the genotype showed 
no significant association between the genotype and potentially-fatal VA (C/C OR 1; 
C/G OR 0.54, CI 0.21 – 1.417, p-value 0.343; G/G OR 0.80, CI 0.198 – 3.236, p-
value 0.907). 
An adjusted model, again showed no significant association between 
genotype and potentially-fatal VA (C/C OR 1; C/G OR 0.632, CI 0.211 – 1.891, p-
value 0.48; G/G OR 0.921, CI 0.194 – 4.374, p-value 0.84) – Table 2. 
 
Potentially-fatal VA and Telomere Length in Different Genotypes: 
The mean telomere length was distributed normally and showed the expected age 
related attrition. The distribution of mean telomere length across different genotypes 
and its association with potentially-fatal VA in the individual genotypes was 
investigated.  
There was no significant difference in mean telomere length between the 
different genotypes. Moreover, the mean telomere length had no association with 
potentially-fatal VA in the individual genotypes (C/C, C/G, G/G; p-value 0.58, 0.68, 
0.73) – Table 3.  
The mean telomere length, however, was shorter in individuals homozygous 
for G allele when compared to the heterozygotes and those homozygous for C allele 
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(CC>CG>GG, mean ± SD 1.25±0.35, 1.17±0.35, 1.1±0.36; p-value CC>GG, 
GG>CG, CG>CC; 0.17, 0.53, 0.32). The difference in telomere lengths across 
genotypes did not achieve significance.  
 
Potentially-fatal VA and Telomerase in Different Genotypes: 
We investigated whether telomerase activity was different across genotypes and if 
there was an association between telomerase activity and genotype with potentially-
fatal VA.  
 In the entire cohort, the mean telomerase activity was highest in individuals 
homozygous for C-allele and was similar across the heterozygous allele and 
individuals homozygous for G allele (C/C 0.35, C/G 0.26, G/G 0.24). 
 The odds of receiving ICD therapy for potentially-fatal VA increase 7.5 fold in 
individuals homozygous for C-allele with each unit increase in telomerase activity. 
There was a strong association between telomerase activity and ICD therapy in the 
C/C genotype (OR 7.507, CI 1.00-56.61, p-value 0.04) – Table 4. This might not 
represent a statistically significant result due to the multiple testing issue of statistical 
analyses. However, the large effect size with an odds ratio greater than seven is 
notable and warrants further investigation. 
No significant association between potentially-fatal VA and telomerase 
activity was found in the C/G genotype (OR 2.759, CI 0.352 – 21.60, p-value 0.33) or 
G/G genotype (OR 4.137, CI 0.117 – 145.91, p-value 0.43) – Table 4. 
Telomerase activity (mean±SD) in patients with and without potentially-fatal 
VA (cases versus controls) in different genotypes is shown in Figure 1. 
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DISCUSSION 
The present study is the first to examine the association between a SNP including 
the TERC locus, telomerase activity, and ventricular arrhythmias in ischaemic 
cardiomyopathy patients. The main finding of this study is that telomerase activity 
was much higher in individuals homozygous for C allele of SNP 12696304 and had a 
significant association with potentially-fatal VA in this genotype only. The odds of 
receiving ICD therapy for potentially-fatal VA increase 7.5 fold in individuals 
homozygous for C-allele with each unit increase in telomerase activity. This 
association with VA was not significant in G homozygous and heterozygous alleles. 
Hence homozygosity for C-allele significantly affected telomerase expression in 
ischaemic cardiomyopathy patients. Increased telomerase activity in individuals with 
C/C genotype is associated with a higher incidence of VA post MI. Whether this 
association is causal or reverse-causal is not known. Also, the genotype 
(independent of the telomerase activity) did not correlate with incidence of VA. 
 Telomere length variability has been attributed to genetic influences. 
Heritability estimates of 78% have been derived from twin studies and account for 
inter-individual differences to a large extent.13 Large scale genotyping studies have 
identified various genetic variants which effect telomere length as they harbour 
genes that encode proteins with known function in telomere biology. These include 
TERC locus on 3q26,20 TERT on 5p15.33, NAF1 (nuclear assembly factor 1) on 
4q32.2, OBFC1 (oligonucleotide/oligosaccharide-binding fold containing 1) 26 and 
RTEL 1 (regulator of telomere elongation helicase 1) on 20q13.3.27-30 TERC and 
TERT are components of the telomerase ribonucleoprotein moiety, whereas NAF1 is 
required for H/ACA box snoRNA assembly, the RNA family to which TERC 
belongs.27 Therefore, the three most significantly-associated loci (3q26, 5p15.33 and 
4q32.2) harbour genes involved in the formation and activity of telomerase. Hence, 
the genetic basis for this variation in telomere length is likely due to the presence of 
telomerase gene variants with variable activity in germ-line and/or stem cell pools. 
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 Of all the genetic loci associated with telomere length we studied the one with 
the most significant association – rs12696304, which is located 1.5kb downstream of 
TERC and shown to be associated with mean telomere length.20 Our study did not 
show a significant difference in mean telomere length across the genotypes. This 
could be due to a small sample size. However, there was a trend towards shorter 
telomere length in individuals homozygous for G allele when compared to the 
heterozygotes and those homozygous for C allele. These findings showed a similar 
trend to those reported in other studies, although at a much smaller scale and in a 
different clinical cohort.22 In addition it was seen that the telomerase activity was 
highest in the C-homozygotes and lowest in the G-homozygotes. This points towards 
the likelihood of the observed genetic variation in telomere length to be mediated via 
TERC expression and may be validated in studies with a larger sample size. 
As telomerase is responsible for maintaining telomere length, factors that 
influence telomerase activity are clearly important when considering the association 
between telomere length and clinical phenotype. However, significant associations 
between telomerase activity and SNP variants have not been shown in previous 
studies and all inferences have been derived from quantitative assessment of mean 
telomere length. The present study shows (1) a significant association between a 
telomere related SNP 12696304 and telomerase activity and (2) a significant 
association between telomerase activity and VA in individuals homozygous for the 
major allele (C) of the same SNP 12696304 post myocardial infarction. Thus, this 
genetic variant effects telomerase activity (and hence telomere length) and is 
significantly associated with the incidence of cardiac arrhythmia in individuals with 
ischaemic cardiomyopathy. 
It is difficult to establish if the observed association is causal in nature within 
the realms of this cross-sectional study. The rise in telomerase activity could be the 
result of ICD therapy itself. Patients received ICD therapy for potentially fatal VA. 
Both the cardiac arrhythmia or ICD therapy itself could potentially affect cellular 
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function and stability leading to an enzyme rise, which is independent of telomeric 
function. However, if this were the case, then one would expect the telomerase levels 
to be proportionate to the number of ICD therapies received. There was no 
significant association between telomerase activity and number of ICD therapies in 
this cohort (n = 90, p = 0.653). Also, if the telomerase rise were solely the result of 
ICD therapy, then it would be difficult to explain why this association was seen 
predominantly in one genotype (homozygous C) despite it not including the patient 
with the maximum number of shocks. Nonetheless, conclusions can only be drawn 
with the availability of longitudinal changes in telomerase across all three alleles, 
before and after ICD therapy, from large-scale prospective studies. 
If telomerase activity were to be causal in arrhythmia occurrence in this group 
of patients, then genetic variation in telomerase expression becomes clinically 
relevant. This genetic variation could predispose some individuals (C-homozygotes) 
to express higher telomerase activity at the time of index event (MI) in anticipation of 
later instability. This would mean that individuals being born with a certain 
predilection (mediated by telomere biology) would develop potentially-fatal VAs, 
should they suffer from a MI. 
In this scenario, the increase in telomerase activity in individuals with C 
homozygous alleles of the SNP encoding TERC would be present prior to the 
development of VA. The increased telomerase expression in these individuals might 
be secondary to an inherited variation in TERC, which only becomes functional 
(increased telomerase activity) on exposure to inflammation and oxidative stress at 
the time of MI. The role of telomerase in arrhythmia prediction here may reflect a 
telomere independent role (driven by compromised telomeric integrity in C-
homozygotes rather than telomere length alone) as a transcription factor driving 
expression of key mitochondrial genes to protect the mitochondrial genome from 
oxidative stress at the time of myocardial infarct. 
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Poor left ventricular function and MI are categorical traits, which might change 
with age or during the course of a disease process like coronary artery disease. 
However, genetic variation in TERC/telomerase expression would be present from 
birth and might become functional at the time of index MI - before (or after) the 
development of left ventricular dysfunction or cardiac arrhythmias. These can thus be 
accurately quantified early on in the disease process. Thus, if increased telomerase 
activity is present in C homozygous alleles of the studied SNP, before development 
of left ventricular dysfunction post MI, then this can be developed as an intermediate 
phenotype to identify individuals prone to VA relatively early on post MI. Again, this 
needs prospective studies to test the validity of the observed associations in this 
study. 
STUDY LIMITATIONS 
Some limitations of this study require consideration. 
Due to the small sample size and absence of longitudinal data it is difficult to 
speculate the clinical relevance of genetic variation in telomerase expression and its 
association with cardiac arrhythmia in this cohort. Hence these findings are 
hypothesis generating. 
The study is limited to Caucasian subjects only. Genetic variation in telomere 
dynamics is likely to be effected by ethnicity. This will need to be considered when 
designing large-scale prospective studies in the future. 
 
CONCLUSION 
This study provides novel insights into genetic determination of telomere biology and 
its association with cardiac arrhythmia in ischaemic cardiomyopathy patients. 
Homozygosity for C-allele of SNP 12696304 significantly effects telomerase 
expression and its association with VA in this cohort. This suggests that variants in 
genes encoding TERC RNA subunit with known function in telomere biology have a 
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functional effect and may modify clinical phenotype. Establishing longitudinal 
changes across genotypes in large-scale prospective studies will be required to 
investigate this further.  
 
 
FIGURE LEGEND 
Figure 1: Telomerase activity (mean±SD) in cases and controls across different 
genotypes is shown here. The X-axis shows cases and controls in different 
genotypes (CC, CG, GG) of the SNP rs12696304 and the Y-axis shows mean 
telomerase activity.. For each genotype, individual data points for telomerase activity 
are shown separately for cases (circles) and controls (troangles). Means and SD 
intervals are shown. It is evident that telomerase activity was significantly different 
between cases and controls in C/C genotype only. 
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TABLES 
Table 1: Baseline demographics of cases and controls included in the study 
 
N = 90 Cases Controls p-value 
Number of patients 35 55  
Age(yrs), mean±SD 69.3±7.6 71.6±8.8 0.19 
White cell count (109/L), 
mean±SD 
7.7±1.7 7.46±1.7 0.43 
Male gender,n(%) 32(91.4) 48(87.3) 0.78 
Diabetes,n(%) 7 (20) 18 (32.7) 0.28 
Hypertension,n(%) 14 (40) 25 (45.4) 0.77 
Follow-up since ICD implant, 
months;mean±SD 
46.5±26.9 38.1±30.5 0.18 
LVEF,%;mean±SD 26.73±7.2 27.24±7.6 0.75 
eGFR, mean±SD 63.94±21.8 60.59±20.22 0.49 
NYHA GradeIII, n(%) 33 (94.28) 50 (90.91) 0.62 
 
 
[Results shown as mean±standard deviation or number of patients and % of total 
group. LVEF: Left Ventricular Ejection Fraction, eGFR: Glomerular Filteration Rate, 
NYHA: New York Heart Association classification] 
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Table 2: Multivariate analysis of Potentially-fatal VA and Genotype 
 
Parameter Odds Ratio 95% Wald 
Confidence Limits 
p-value 
SNP C/C 1 - - 
SNP C/G 0.632 0.211 – 1.891 0.48 
SNP G/G 0.921 0.194 – 4.374 0.84 
Gender 0.845 0.138 – 5.158 0.85 
Age 0.938 0.885 – 0.993 0.03 
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Table 3: Potentially-fatal VA and mean telomere length in different genotypes 
of SNP rs12696304 
 
Parameter Odds ratio 95% Wald 
Confidence Limits 
p-value 
Mean telomere length in 
C/C genotype 
1.06 0.86 – 1.32 0.58 
 
Mean telomere length in 
C/G genotype 
0.91 0.57 – 1.44 0.68 
Mean telomere length in 
G/G genotype 
0.92 0.55 – 1.52 0.73 
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Table 4: Potentially-fatal VA and telomerase activity in different genotypes of 
SNP rs12696304 
 
Parameter Odds Ratio 95% Wald 
Confidence 
Limits 
p-value 
Telomerase activity in 
C/C genotype 
7.507 1.00 – 56.61 0.04 
Telomerase activity in 
C/G genotype 
2.759 0.352 – 21.60 0.33 
 
Telomerase activity in 
G/G genotype 
4.137 0.117 – 145.91 0.43 
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Figure 1: Telomerase activity (mean±SD) in cases and controls across 
different genotypes 
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